Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay

G. Wynne Aherne, Anthea Hardcastle, Melanie Valenti, Alexander Bryant, Paul Rogers, George Pettit, Jayaram K. Srirangam, Lloyd R. Kelland

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Dolastatins 10 and 15 are small peptides isolated from the marine sea hare Dolabella auricularia that have been shown to interact with tubulin. Their growth-inhibitory properties were compared using panels of human ovarian and colon-carcinoma cell lines. Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10-10 and 2.1 x 10-9 M, respectively; P < 0.053] and more potent than paclitaxel or vinblastine. While neither dolastatin exhibited marked cross-resistance in cisplatin- or etoposide-resistant cell lines, contrasting effects were observed using an acquired doxorubicin-resistant (CH1doxR, 100-fold resistant, P-glycoprotein overexpressing) cell line. Resistance was significantly higher to dolastatin 15 (12.7-fold) than to dolastatin 10 (only 3.2-fold; P < 0.05) and was reversible in both cases by verapamil. In vivo, using a s.c. advanced-stage human ovarian carcinoma xenograft and equitoxic doses, greater activity was observed with dolastatin 10 (6.1-day growth delay) versus 0.4 days for dolastatin 15. A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed. The rabbit antiserum also cross-reacted by 65% with dolastatin 15. Comparative mouse pharmacokinetics following i.v. administration of 1 mg/kg showed that both compounds are rapidly eliminated, but with a shorter second-phase half-life (t 1/2 β) being observed dolastatin 15 (being detectable for only up to 4 h post-administration), the t 1/2 β being 3 times longer for dolastatin 10. In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h). Plasma binding of dolastatin 10 exceeded 90%. The highly sensitive RIA will be useful for pharmacokinetic studies in conjunction with the planned phase I clinical trials of these novel, extremely potent, tubulin-binding agents, of which dolastatin 10 appears to possess the more promising preclinical features.

Original languageEnglish (US)
Pages (from-to)225-232
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume38
Issue number3
DOIs
StatePublished - 1996

Fingerprint

dolastatin 10
Radioimmunoassay
Plasmas
Pharmacokinetics
Cells
Tubulin
Cell Line
Inhibitory Concentration 50
Carcinoma
Hares
dolastatin 15
Growth Inhibitors
Clinical Trials, Phase I
Vinblastine
P-Glycoprotein
Etoposide

Keywords

  • Cytotoxicity
  • Dolastatins
  • P-glycoprotein
  • Radioimmunoassay
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology
  • Toxicology
  • Pharmacology (medical)

Cite this

Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. / Aherne, G. Wynne; Hardcastle, Anthea; Valenti, Melanie; Bryant, Alexander; Rogers, Paul; Pettit, George; Srirangam, Jayaram K.; Kelland, Lloyd R.

In: Cancer Chemotherapy and Pharmacology, Vol. 38, No. 3, 1996, p. 225-232.

Research output: Contribution to journalArticle

Aherne, GW, Hardcastle, A, Valenti, M, Bryant, A, Rogers, P, Pettit, G, Srirangam, JK & Kelland, LR 1996, 'Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay', Cancer Chemotherapy and Pharmacology, vol. 38, no. 3, pp. 225-232. https://doi.org/10.1007/s002800050475
Aherne, G. Wynne ; Hardcastle, Anthea ; Valenti, Melanie ; Bryant, Alexander ; Rogers, Paul ; Pettit, George ; Srirangam, Jayaram K. ; Kelland, Lloyd R. / Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. In: Cancer Chemotherapy and Pharmacology. 1996 ; Vol. 38, No. 3. pp. 225-232.
@article{ad3250c857fd4f598498ff49a5b00487,
title = "Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay",
abstract = "Dolastatins 10 and 15 are small peptides isolated from the marine sea hare Dolabella auricularia that have been shown to interact with tubulin. Their growth-inhibitory properties were compared using panels of human ovarian and colon-carcinoma cell lines. Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50{\%} inhibitory concentrations (IC50 values) 2.3 x 10-10 and 2.1 x 10-9 M, respectively; P < 0.053] and more potent than paclitaxel or vinblastine. While neither dolastatin exhibited marked cross-resistance in cisplatin- or etoposide-resistant cell lines, contrasting effects were observed using an acquired doxorubicin-resistant (CH1doxR, 100-fold resistant, P-glycoprotein overexpressing) cell line. Resistance was significantly higher to dolastatin 15 (12.7-fold) than to dolastatin 10 (only 3.2-fold; P < 0.05) and was reversible in both cases by verapamil. In vivo, using a s.c. advanced-stage human ovarian carcinoma xenograft and equitoxic doses, greater activity was observed with dolastatin 10 (6.1-day growth delay) versus 0.4 days for dolastatin 15. A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed. The rabbit antiserum also cross-reacted by 65{\%} with dolastatin 15. Comparative mouse pharmacokinetics following i.v. administration of 1 mg/kg showed that both compounds are rapidly eliminated, but with a shorter second-phase half-life (t 1/2 β) being observed dolastatin 15 (being detectable for only up to 4 h post-administration), the t 1/2 β being 3 times longer for dolastatin 10. In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h). Plasma binding of dolastatin 10 exceeded 90{\%}. The highly sensitive RIA will be useful for pharmacokinetic studies in conjunction with the planned phase I clinical trials of these novel, extremely potent, tubulin-binding agents, of which dolastatin 10 appears to possess the more promising preclinical features.",
keywords = "Cytotoxicity, Dolastatins, P-glycoprotein, Radioimmunoassay, Xenograft",
author = "Aherne, {G. Wynne} and Anthea Hardcastle and Melanie Valenti and Alexander Bryant and Paul Rogers and George Pettit and Srirangam, {Jayaram K.} and Kelland, {Lloyd R.}",
year = "1996",
doi = "10.1007/s002800050475",
language = "English (US)",
volume = "38",
pages = "225--232",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay

AU - Aherne, G. Wynne

AU - Hardcastle, Anthea

AU - Valenti, Melanie

AU - Bryant, Alexander

AU - Rogers, Paul

AU - Pettit, George

AU - Srirangam, Jayaram K.

AU - Kelland, Lloyd R.

PY - 1996

Y1 - 1996

N2 - Dolastatins 10 and 15 are small peptides isolated from the marine sea hare Dolabella auricularia that have been shown to interact with tubulin. Their growth-inhibitory properties were compared using panels of human ovarian and colon-carcinoma cell lines. Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10-10 and 2.1 x 10-9 M, respectively; P < 0.053] and more potent than paclitaxel or vinblastine. While neither dolastatin exhibited marked cross-resistance in cisplatin- or etoposide-resistant cell lines, contrasting effects were observed using an acquired doxorubicin-resistant (CH1doxR, 100-fold resistant, P-glycoprotein overexpressing) cell line. Resistance was significantly higher to dolastatin 15 (12.7-fold) than to dolastatin 10 (only 3.2-fold; P < 0.05) and was reversible in both cases by verapamil. In vivo, using a s.c. advanced-stage human ovarian carcinoma xenograft and equitoxic doses, greater activity was observed with dolastatin 10 (6.1-day growth delay) versus 0.4 days for dolastatin 15. A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed. The rabbit antiserum also cross-reacted by 65% with dolastatin 15. Comparative mouse pharmacokinetics following i.v. administration of 1 mg/kg showed that both compounds are rapidly eliminated, but with a shorter second-phase half-life (t 1/2 β) being observed dolastatin 15 (being detectable for only up to 4 h post-administration), the t 1/2 β being 3 times longer for dolastatin 10. In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h). Plasma binding of dolastatin 10 exceeded 90%. The highly sensitive RIA will be useful for pharmacokinetic studies in conjunction with the planned phase I clinical trials of these novel, extremely potent, tubulin-binding agents, of which dolastatin 10 appears to possess the more promising preclinical features.

AB - Dolastatins 10 and 15 are small peptides isolated from the marine sea hare Dolabella auricularia that have been shown to interact with tubulin. Their growth-inhibitory properties were compared using panels of human ovarian and colon-carcinoma cell lines. Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10-10 and 2.1 x 10-9 M, respectively; P < 0.053] and more potent than paclitaxel or vinblastine. While neither dolastatin exhibited marked cross-resistance in cisplatin- or etoposide-resistant cell lines, contrasting effects were observed using an acquired doxorubicin-resistant (CH1doxR, 100-fold resistant, P-glycoprotein overexpressing) cell line. Resistance was significantly higher to dolastatin 15 (12.7-fold) than to dolastatin 10 (only 3.2-fold; P < 0.05) and was reversible in both cases by verapamil. In vivo, using a s.c. advanced-stage human ovarian carcinoma xenograft and equitoxic doses, greater activity was observed with dolastatin 10 (6.1-day growth delay) versus 0.4 days for dolastatin 15. A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed. The rabbit antiserum also cross-reacted by 65% with dolastatin 15. Comparative mouse pharmacokinetics following i.v. administration of 1 mg/kg showed that both compounds are rapidly eliminated, but with a shorter second-phase half-life (t 1/2 β) being observed dolastatin 15 (being detectable for only up to 4 h post-administration), the t 1/2 β being 3 times longer for dolastatin 10. In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h). Plasma binding of dolastatin 10 exceeded 90%. The highly sensitive RIA will be useful for pharmacokinetic studies in conjunction with the planned phase I clinical trials of these novel, extremely potent, tubulin-binding agents, of which dolastatin 10 appears to possess the more promising preclinical features.

KW - Cytotoxicity

KW - Dolastatins

KW - P-glycoprotein

KW - Radioimmunoassay

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=0029953141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029953141&partnerID=8YFLogxK

U2 - 10.1007/s002800050475

DO - 10.1007/s002800050475

M3 - Article

C2 - 8646796

AN - SCOPUS:0029953141

VL - 38

SP - 225

EP - 232

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -